Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Earnings Results, Beats Estimates By $0.09 EPS

Key Points

• Kiniksa topped Q1 estimates with GAAP EPS of $0.27 versus consensus ~$0.18 and revenue of $214.3M (≈+55–56% YoY), and raised FY‑2026 net product revenue guidance to $930M–$945M.
• ARCALYST drove commercial momentum—~400 new prescribers in Q1 (total >4,550) and a new AI‑driven DTC campaign—and the pipeline shows near‑term catalysts with KPL‑387 dose‑focusing data expected H2‑2026 and a Phase 3 planned by year‑end, while KPL‑1161 targets Phase I entry by year‑end.
• Financial strength and market reaction: Q1 net income rose to $22.6M with cash of $468.1M, shares jumped ~23.5% after the report, and analysts lifted targets (consensus: Moderate Buy).

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09, FiscalAI reports. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.11 earnings per share.

Here are the key takeaways from Kiniksa Pharmaceuticals International's conference call:

• ARCALYST delivered $214.3 million in Q1 net revenue (+56% YoY) and the company raised full‑year 2026 revenue guidance to $930M–$945M (from $900M–$920M).
• Commercial momentum accelerated with ~400 new prescribers in Q1 (the largest quarterly gain since launch) bringing total prescribers to >4,550, and Kiniksa launched a targeted, AI‑driven DTC campaign ("Heart's Home") intended to cost‑effectively drive patient‑initiated prescribing.
• The company adjusted its copay assistance program to reduce average copay payouts, which helped gross‑to‑net versus prior year, but Q1 gross‑to‑net was higher than Q4 and remains exposed to seasonal payer dynamics and co‑pay resets.
• Pipeline progress — the integrated KPL‑387 phase II/III is on track with dose‑focusing data expected in H2 2026 and phase III planned to start by year‑end 2026, and KPL‑1161 is targeted to enter phase I by year‑end.
• Financial strength — Q1 net income rose to $22.6 million (vs. $8.5M a year ago), ARCALYST collaboration profit was up 73% to $151.2 million, and cash totaled $468.1 million, with management expecting to remain cash‑flow positive on an annual basis.

Kiniksa Pharmaceuticals International Trading Up 23.5%

Shares of NASDAQ:KNSA opened at $53.85 on Wednesday. The stock's 50-day moving average price is $46.11 and its 200-day moving average price is $42.97. Kiniksa Pharmaceuticals International has a 12-month low of $22.23 and a 12-month high of $54.23. The stock has a market capitalization of $4.12 billion, a P/E ratio of 72.77 and a beta of 0.06.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 7,278 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $50.01, for a total value of $363,972.78. Following the completion of the sale, the chief executive officer owned 7,278 shares of the company's stock, valued at approximately $363,972.78. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 12,528 shares of the firm's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total value of $567,142.56. Following the transaction, the director owned 12,546 shares in the company, valued at approximately $567,957.42. The trade was a 49.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 61,479 shares of company stock valued at $2,832,812. 53.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Orion Porfolio Solutions LLC purchased a new position in Kiniksa Pharmaceuticals International during the third quarter valued at $342,000. Brooklyn Investment Group increased its stake in shares of Kiniksa Pharmaceuticals International by 629.3% in the 3rd quarter. Brooklyn Investment Group now owns 8,482 shares of the company's stock worth $329,000 after acquiring an additional 7,319 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company's stock worth $317,000 after acquiring an additional 508 shares in the last quarter. XTX Topco Ltd purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $291,000. Finally, Virtu Financial LLC purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $267,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an "outperform" rating in a research note on Thursday, April 16th. Zacks Research cut Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research note on Friday, April 17th. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a "buy" rating in a research report on Tuesday. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a "buy" rating and a $62.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of "Moderate Buy" and a consensus target price of $58.43.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 results beat expectations — GAAP EPS of $0.27 (versus street ~ $0.18–$0.21) and revenue of $214.3M, up ~55% year-over-year, demonstrating solid top- and bottom-line execution. KNSA Tops Q1 Earnings and Revenue Estimates (Zacks)
• Positive Sentiment: Company raised FY‑2026 net product revenue guidance to $930M–$945M (above consensus ~ $912.7M), signaling confidence in continued ARCALYST sales momentum. Kiniksa Reports Q1 Results and Portfolio Execution (GlobeNewswire)
• Positive Sentiment: ARCALYST product strength: Q1 net product revenue ~$214.3M (≈56% YoY growth); management increased ARCALYST 2026 expectations — core driver of revenue upside. Kiniksa Q1 Product Revenue Details (GlobeNewswire)
• Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026, with a Phase 3 pivotal trial planned to start by year‑end — potential near‑term clinical catalysts. KPL‑387 Development Update (GlobeNewswire)
• Positive Sentiment: Analyst upgrade/price target lift: Jefferies raised its price target from $58 to $71 and reiterated a buy rating, providing an institutional endorsement that supports further upside. Jefferies Raises KNSA Price Target (TickerReport)
• Positive Sentiment: Balance sheet: cash increased to ~$468.1M at quarter‑end, giving the company capital to fund growth and trials without immediate financing risk. Q1 Cash Balance (GlobeNewswire)
• Neutral Sentiment: Analyst expectations: the consensus outlook cited in reports implies expected FY EPS ~1.09; while Q1 beat supports that view, investors will watch whether margin trends and R&D timing sustain consensus. Earnings Call Transcript (Seeking Alpha)

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.